Barclays increased their price target on shares of Vertex Pharmaceuticals from $384.00 to $399.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 2nd.

Source: https://www.dailypolitical.com/2023/11/23/2420-shares-in-vertex-pharmaceuticals-incorporated-nasdaqvrtx-bought-by-edgestream-partners-l-p.html

California State Teachers Retirement System lowered its stake in shares of Vertex Pharmaceuticals Incorporated () by 1.8% during the 2nd quarter, according to the company in its most recent filing with the SEC.

Source: https://www.americanbankingnews.com/2023/12/14/california-state-teachers-retirement-system-sells-7960-shares-of-vertex-pharmaceuticals-incorporated-nasdaqvrtx.html

Cantor Fitzgerald reissued an “overweight” rating and issued a $380.00 target price on shares of Vertex Pharmaceuticals in a report on Thursday.

Source: https://www.americanbankingnews.com/2023/12/17/alberta-investment-management-corp-sells-183-shares-of-vertex-pharmaceuticals-incorporated-nasdaqvrtx.html

CRSP also will get $200M from its partner Vertex Pharmaceuticals () if/when exa-cel is approved.

Source: https://seekingalpha.com/article/4654099-crispr-cas9-gene-editing-is-on-the-cusp-of-something-big?source=feed_all_articles

Drive Wealth Management LLC purchased a new position in shares of Vertex Pharmaceuticals during the 1st quarter valued at $262,000.

Source: https://www.etfdailynews.com/2023/06/26/hb-wealth-management-llc-grows-stock-holdings-in-vertex-pharmaceuticals-incorporated-nasdaqvrtx/

Empirical Finance LLC lifted its position in Vertex Pharmaceuticals by 5.5% during the 2nd quarter.

Source: https://www.etfdailynews.com/2023/01/26/avantax-advisory-services-inc-has-338000-stock-holdings-in-vertex-pharmaceuticals-incorporated-nasdaqvrtx/

Evercore ISI increased their target price on shares of Vertex Pharmaceuticals from $375.00 to $379.00 in a research note on Monday, June 26th.

Source: https://www.etfdailynews.com/2023/10/21/baldwin-investment-management-llc-grows-position-in-vertex-pharmaceuticals-incorporated-nasdaqvrtx/

Finally, Macquarie Group Ltd. raised its holdings in Vertex Pharmaceuticals by 232.3% in the 2nd quarter.

Source: https://www.americanbankingnews.com/2023/09/22/level-four-advisory-services-llc-purchases-35-shares-of-vertex-pharmaceuticals-incorporated-nasdaqvrtx.html

HC Wainwright lifted their price objective on shares of Vertex Pharmaceuticals from $300.00 to $325.00 and gave the company a “buy” rating in a research note on Wednesday, February 8th.

Source: https://www.etfdailynews.com/2023/04/03/135-shares-in-vertex-pharmaceuticals-incorporated-nasdaqvrtx-purchased-by-rfp-financial-group-llc/

Independence Bank of Kentucky purchased a new position in Vertex Pharmaceuticals during the second quarter valued at approximately $25,000.

Source: https://www.dailypolitical.com/2023/08/10/canaccord-genuity-group-increases-vertex-pharmaceuticals-nasdaqvrtx-price-target-to-315-00.html

In other news, CEO sold 3,317 shares of Vertex Pharmaceuticals stock in a transaction on Thursday, April 27th.

Source: https://www.etfdailynews.com/2023/07/15/d-a-davidson-co-has-1-19-million-stock-holdings-in-vertex-pharmaceuticals-incorporated-nasdaqvrtx/

LSV Asset Management lifted its holdings in shares of Vertex Pharmaceuticals by 206.3% during the 1st quarter.

Source: https://www.dailypolitical.com/2023/05/04/barclays-boosts-vertex-pharmaceuticals-nasdaqvrtx-price-target-to-384-00.html

New Hampshire Trust acquired a new position in Vertex Pharmaceuticals in the fourth quarter worth about $29,000.

Source: https://www.americanbankingnews.com/2023/07/14/concord-wealth-partners-raises-stock-holdings-in-vertex-pharmaceuticals-incorporated-nasdaqvrtx.html

Steward Financial Group LLC acquired a new stake in Vertex Pharmaceuticals in the 4th quarter valued at about $28,000.

Source: https://www.americanbankingnews.com/2023/08/06/commerce-bank-has-2-13-million-stock-position-in-vertex-pharmaceuticals-incorporated-nasdaqvrtx.html

Vertex Pharmaceuticals Incorporated has a 52-week low of $271.61 and a 52-week high of $354.94.

Source: https://www.americanbankingnews.com/2023/07/13/100-shares-in-vertex-pharmaceuticals-incorporated-nasdaqvrtx-acquired-by-arlington-partners-llc.html

Vertex Pharmaceuticals, the firm is optimistic that the Food and Drug Administration will soon approve their gene-editing breakthrough for treating sickle cell disease and transfusion-dependent beta-thalassemia.

Source: https://investorplace.com/2023/01/3-gene-editing-stocks-with-the-best-long-term-potential/

William Blair started coverage on shares of Vertex Pharmaceuticals in a research report on Tuesday, May 30th.

Source: https://www.dailypolitical.com/2023/08/10/canaccord-genuity-group-increases-vertex-pharmaceuticals-nasdaqvrtx-price-target-to-315-00.html